Parity, pregnancy and neonatal outcomes in women treated for hyperprolactinaemia compared with a control group

Clinical Endocrinology

Volumn 67, Issue 3, 2007, Pages 393-397

  Berinder, Katarina ^a,b   Hulting, Anna Lena ^a,b   Granath, Fredrik ^b   Hirschberg, Angelica Lindén ^a,b   Akre, Olof ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; PROLACTIN;

ADULT; ANALYSIS OF VARIANCE; APGAR SCORE; ARTICLE; BIRTH WEIGHT; CESAREAN SECTION; CONGENITAL MALFORMATION; CONTROLLED STUDY; FEMALE; FEMALE INFERTILITY; HUMAN; HYPERPROLACTINEMIA; INFORMATION RETRIEVAL; LABOR INDUCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MATERNAL AGE; NEWBORN CARE; PARITY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; REGISTER; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; APGAR SCORE; FEMALE; HUMANS; HYPERPROLACTINEMIA; INFANT, NEWBORN; INFERTILITY, FEMALE; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; REGISTRIES; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 34548013741     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02897.x     Document Type: Article

References (33)

1. Molitch, M.E., Elton, R.L., Blackwell, R.E., Caldwell, B., Chang, R.J., Jaffe, R., Joplin, G., Robbins, R.J., Tyson, J. Thorner, M.O. (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. Journal of Clinical Endocrinology and Metabolism, 60, 698 705.
2. Bevan, J.S., Webster, J., Burke, C.W. Scanlon, M.F. (1992) Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews, 13, 220 240.
3. Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., Mahler, C., Stevenaert, A., Verlooy, J., Raftopoulos, C. Beckers, A. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism, 84, 2518 2522.
4. Berinder, K., Stackenas, I., Akre, O., Hirschberg, A.L. Hulting, A.L. (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clinical Endocrinology, 63, 450 455.
5. Weil, C. (1986) The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Current Medical Research Opinion, 10, 172 195.
6. Molitch, M.E. (2003) Pituitary tumors and pregnancy. Growth Hormone & IGF Research, 13, 38 44.
7. Crosignani, P.G., Mattei, A.M., Scarduelli, C., Cavioni, V. Boracchi, P. (1989) Is pregnancy the best treatment for hyperprolactinaemia? Human Reproduction, 4, 910 912.
8. Crosignani, P.G., Mattei, A.M., Severini, V., Cavioni, V., Maggioni, P. Testa, G. (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. European Journal of Obstetrics & Gynecology and Reproductive Biology, 44, 175 180.
9. Mornex, R. Hugues, B. (1991) Remission of hyperprolactinemia after pregnancy. New England Journal of Medicine, 324, 60.
10. Ampudia, X., Puig-Domingo, M., Schwarzstein, D., Corcoy, R., Espinos, J.J., Calaf-Alsina, J. Webb, S.M. (1992) Outcome and long-term effects of pregnancy in women with hyperprolactinaemia. European Journal of Obstetrics & Gynecology and Reproductive Biology, 46, 101 107.
11. Jeffcoate, W.J., Pound, N., Sturrock, N.D. Lambourne, J. (1996) Long-term follow-up of patients with hyperprolactinaemia. Clinical Endocrinology, 45, 299 303.
12. Griffith, R.W., Turkalj, I. Braun, P. (1978) Outcome of pregnancy in mothers given bromocriptine. British Journal of Clinical Pharmacology, 5, 227 231.
13. Turkalj, I., Braun, P. Krupp, P. (1982) Surveillance of bromocriptine in pregnancy. JAMA, 247, 1589 1591.
14. Molitch, M.E. (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary, 5, 55 65.
15. Krupp, P. Monka, C. (1987) Bromocriptine in pregnancy: safety aspects. Klinische Wochenschrift, 65, 823 827.
16. Raymond, J.P., Goldstein, E., Konopka, P., Leleu, M.F., Merceron, R.E. Loria, Y. (1985) Follow-up of children born of bromocriptine-treated mothers. Hormone Research, 22, 239 246.
17. Bronstein, M.D. (2005) Prolactinomas and pregnancy. Pituitary, 8, 31 38.
18. Gillam, M.P., Molitch, M.E., Lombardi, G. Colao, A. (2006) Advances in the treatment of prolactinomas. Endocrine Reviews, 27, 485 534.
19. Ruiz-Velasco, V. Tolis, G. (1984) Pregnancy in hyperprolactinemic women. Fertility and Sterility, 41, 793 805.
20. Konopka, P., Raymond, J.P., Merceron, R.E. Seneze, J. (1983) Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. American Journal of Obstetrics and Gynecology, 146, 935 938.
21. de Wit, W., Coelingh Bennink, H.J. Gerards, L.J. (1984) Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnancies. British Journal of Obstetrics and Gynaecology, 91, 1059 1069.
22. Robert, E., Musatti, L., Piscitelli, G. Ferrari, C.I. (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reproductive Toxicology, 10, 333 337.
23. Ricci, E., Parazzini, F., Motta, T., Ferrari, C.I., Colao, A., Clavenna, A., Rocchi, F., Gangi, E., Paracchi, S., Gasperi, M., Lavezzari, M., Nicolosi, A.E., Ferrero, S., Landi, M.L., Beck-Peccoz, P. Bonati, M. (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology, 16, 791 793.
24. Ciccarelli, E., Grottoli, S., Razzore, P., Gaia, D., Bertagna, A., Cirillo, S., Cammarota, T., Camanni, M. Camanni, F. (1997) Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. Journal of Endocrinological Investigations, 20, 547 551.
25. Shoham, Z., Homburg, R. Jacobs, H.S. (1991) CV 205-502 - effectiveness, tolerability, and safety over 24-month study. Fertility and Sterility, 55, 501 506.
26. Morange, I., Barlier, A., Pellegrini, I., Brue, T., Enjalbert, A. Jaquet, P. (1996) Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology, 135, 413 420.
27. Webster, J. (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Safety, 14, 228 238.
28. Barlier, A. Jaquet, P. (2006) Quinagolide - a valuable treatment option for hyperprolactinaemia. European Journal of Endocrinology, 154, 187 195.
29. The Swedish Medical Birth Register 2003) A Summary of Content and Quality. The National Board of Health and Welfare, Stockholm.
30. Lindmark, G. Cnattingius, S. (1991) The scientific basis of antenatal care. Report from a state-of-the-art conference. Acta Obstetrica et Gynecologica Scandinavica, 70, 105 109.
31. Hogberg, U. Larsson, N. (1997) Early dating by ultrasound and perinatal outcome. A cohort study. Acta Obstetrica et Gynecologica Scandinavica, 76, 907 912.
32. Molitch, M.E. (1999) Medical treatment of prolactinomas. Endocrinology and Metabolism Clinics of North America, 28, 143 169.
33. Liu, C. Tyrrell, J.B. (2001) Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary, 4, 179 185.